tirzepatide vs semaglutide risks Tirzepatide vs. Semaglutide: Which Is
Description
At least one treatment-emergent nervous system disorder adverse event occurred in 15.8% of the tirzepatide group and 13% of the placebo group
Protocol: Restart or increase tirzepatide dose with provider guidance
All authors edited the final manuscript draft and approved the final version for publication
Mounjaro launched in 2022 after FDA approval for type 2 diabetes
